Shares of Cara Therapeutics CARA rose 0.62% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share rose 52.70% year over year to ($0.35), which beat the estimate of ($0.60).
Revenue of $9,266,000 higher by 60.17% year over year, which beat the estimate of $4,770,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
Details Of The Call
Date: Nov 09, 2020
Time: 04:30 PM
ET Webcast URL: https://edge.media-server.com/mmc/p/42euzka8
Recent Stock Performance
Company's 52-week high was at $26.67
Company's 52-week low was at $8.88
Price action over last quarter: down 16.75%
Company Profile
Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
